Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key

GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma

Showing 43 of 43 matching drugs for FGR — including drugs targeting any of its 7 synthetic-lethal partners , sorted by total cancer coverage.

Drug	Target	Relationship	Reposition	#cancers
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib	FGR	Direct		3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment	FGR	Direct		2
afatinib, dasatinib, palbociclib, everolimus, olaparib	FGR	Direct		1
bevacizumab, dasatinib, placebo	FGR	Direct		1
bosutinib	FGR	Direct		1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride	FGR	Direct		1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method	FGR	Direct		1
dasatinib, laboratory biomarker analysis, physiologic testing	FGR	Direct		1
dasatinib, mfolfox6	FGR	Direct		1
dasatinib, pharmacological study	FGR	Direct		1
dasatinib, temozolomide, placebo, radiation therapy	FGR	Direct		1
dasatinib	FGR	Direct	yes	0
vandetanib	FGR	Direct	yes	0
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib	SRC	SSL via SRC		3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib	YES1	SSL via YES1		2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment	SRC	SSL via SRC		2
nintedanib	SRC	SSL via SRC		2
nintedanib, pembrolizumab	SRC	SSL via SRC		2
afatinib, dasatinib, palbociclib, everolimus, olaparib	SRC	SSL via SRC		1
afatinib, dasatinib, palbociclib, everolimus, olaparib	YES1	SSL via YES1		1
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment	YES1	SSL via YES1		1
bevacizumab, dasatinib, placebo	SRC	SSL via SRC		1
bevacizumab, dasatinib, placebo	YES1	SSL via YES1		1
bosutinib	SRC	SSL via SRC	yes	1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab	SRC	SSL via SRC		1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride	SRC	SSL via SRC		1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride	YES1	SSL via YES1		1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method	SRC	SSL via SRC		1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method	YES1	SSL via YES1		1
dasatinib, laboratory biomarker analysis, physiologic testing	SRC	SSL via SRC		1
dasatinib, laboratory biomarker analysis, physiologic testing	YES1	SSL via YES1		1
dasatinib, mfolfox6	SRC	SSL via SRC		1
dasatinib, mfolfox6	YES1	SSL via YES1		1
dasatinib, pharmacological study	SRC	SSL via SRC		1
dasatinib, pharmacological study	YES1	SSL via YES1		1
dasatinib, temozolomide, placebo, radiation therapy	SRC	SSL via SRC		1
dasatinib, temozolomide, placebo, radiation therapy	YES1	SSL via YES1		1
ponatinib	SRC	SSL via SRC		1
dasatinib	SRC	SSL via SRC	yes	0
dasatinib	YES1	SSL via YES1	yes	0
tirbanibulin	SRC	SSL via SRC	yes	0
vandetanib	SRC	SSL via SRC	yes	0
vandetanib	YES1	SSL via YES1	yes	0

Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.